STRO Sutro Biopharma Inc.

9.45
-0.92  -9%
Previous Close 10.37
Open 10.2
Price To Book 1.65
Market Cap 216645417
Shares 22,925,441
Volume 26,306
Short Ratio
Av. Daily Volume 24,982

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 initial safety data due at EHA June 13-16, 2019.
STRO-001
Non-Hodgkin lymphoma (NHL)
Phase 1 initiation announced March 15, 2019.
STRO-002
Ovarian and Endometrial Cancer

Latest News

  1. How free-flowing cash is accelerating small companies' cancer drug trials
  2. Sutro Biopharma to Present at the 18th Annual Needham Healthcare Conference
  3. Sutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments
  4. Sutro Biopharma Initiates Phase I Clinical Trial of STRO-002 for the Treatment of Ovarian and Endometrial Cancers
  5. Sutro Biopharma to Present at the Cowen and Company 39th Annual Health Care Conference
  6. Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry
  7. Sutro to Present at 37th Annual J.P. Morgan Healthcare Conference
  8. DAFNA Capital Management Return, AUM and Holdings
  9. Sutro Achieves $10 Million Milestone Payment from Celgene
  10. This year's Bay Area IPO batch remains up 44% despite market turbulence
  11. Sutro to Participate in the 30th Annual Piper Jaffray Healthcare Conference
  12. Sutro Biopharma Reports Third Quarter 2018 Financial Results
  13. Sutro Announces IND Submission and Conclusion of 30-Day Review Period for STRO-002, an Antibody-Drug Conjugate (ADC) Targeting Anti-Folate Receptor-α for Treatment of Ovarian and Endometrial Cancer
  14. Sutro Appoints Industry Veteran Shalini Sharp to Board of Directors
  15. Sutro's STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma
  16. 24 Bay Area companies have gone public so far this year. Here's how they've done.
  17. Sutro Biopharma Announces $85.0 Million Initial Public Offering
  18. The IPO Outlook For The Week: Smart Appliances, A Language App and Drugmakers